Neurology, Alfred Health, Melbourne, Victoria, Australia
Department of Neuroscience, Monash University, Clayton, Victoria, Australia.
J Neurol Neurosurg Psychiatry. 2021 Dec;92(12):1325-1334. doi: 10.1136/jnnp-2020-324674. Epub 2021 Jan 25.
Migraine is the second largest cause of years lost to disability globally among all diseases, with a worldwide prevalence over 1 billion. Despite the global burden of migraine, few classes of therapeutics have been specifically developed to combat migraine. After 30 years of translational research, calcitonin gene-related peptide (CGRP) inhibitors have emerged as a promising new tool in the prevention of migraine. Like all new therapeutics; however, we have limited real-world experience and CGRP has several known systemic actions that warrant consideration. This article provides a narrative review of the evidence for CGRP antagonists and summarises the known and potential side effects that should be considered.
偏头痛是全球所有疾病中导致残疾年数第二大的疾病，全球患病率超过 10 亿。尽管偏头痛的全球负担沉重，但专门用于治疗偏头痛的治疗药物类别却很少。经过 30 年的转化研究，降钙素基因相关肽（CGRP）抑制剂已成为预防偏头痛的一种有前途的新工具。然而，与所有新的治疗药物一样，我们的实际经验有限，而且 CGRP 具有几种已知的全身作用，值得关注。本文对 CGRP 拮抗剂的证据进行了叙述性综述，并总结了应考虑的已知和潜在的副作用。
